AI-generated summary
The authors ran a double-blind factorial feasibility study in 67 patients with advanced cancer and poor sleep, randomised to bright light therapy, melatonin, methylphenidate, combinations, or placebo for two weeks. They report that the approach was feasible, with 81% completing the study, and that bright light therapy was associated with a moderate improvement in sleep quality scores, while no significant changes were seen for other measures. The authors note that larger studies are needed.
- Participants
- 67
- Who or what was studied
- Patients with advanced cancer and poor sleep quality (PSQI of 5 or higher)
- Limits stated in the abstract
- The abstract describes a feasibility study with a small sample across many arms, and the authors state that larger studies are needed to confirm the findings.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on spcare.bmj.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Effect size, Depression, Insomnia, Bright light therapy, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.